Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 6, 2010, Pages 3216-3225

  Peng, Shaomin ^a,b   Adelman, Ron A ^a   Rizzolo, Lawrence J ^a  

^a YALE UNIVERSITY   (United States)

^b HARBIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CLAUDIN; CLAUDIN 10; CLAUDIN 15; CLAUDIN 19; CLAUDIN 3; POTASSIUM ION; RANIBIZUMAB; SODIUM ION; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MACROGOL DERIVATIVE; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOMETHOXYPOLYETHYLENE GLYCOL; POTASSIUM; SODIUM; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOCYTOSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOREACTIVITY; ION CONDUCTANCE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; TIGHT JUNCTION; TRANSCYTOSIS; BLOOD RETINA BARRIER; CAPILLARY PERMEABILITY; CELL CULTURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENETICS; IMMUNOBLOTTING; IMPEDANCE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; CELLS, CULTURED; CLAUDINS; ELECTRIC IMPEDANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION; HUMANS; IMMUNOBLOTTING; POLYETHYLENE GLYCOLS; POTASSIUM; RETINAL PIGMENT EPITHELIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SODIUM; TIGHT JUNCTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953264746     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4162     Document Type: Article

References (56)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900-1901.
2. Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsino-poulos I, Pavesio CE. Macular edema. Surv Ophthalmol. 2004;49: 470-490.
3. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642.
4. Fleckenstein M, Charbel Issa P, Helb HM, et al. High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:4137-4144.
5. Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res. 2008;27:372-390.
6. Izumi-Nagai K, Nagai N, Ohgami K, et al. Inhibition of choroidal neovascularization with an anti-inflammatory carotenoid astaxan-thin. Invest Ophthalmol Vis Sci. 2008;49:1679-1685.
7. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
8. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004;122:598-614.
9. Korte GE, Burns MS, Bellhorn RV. Epithelium-capillary interactions in the eye: the retinal pigment epithelium and the choriocapillaris. Int Rev Cytol. 1989;114:221-248.
10. Yokomori H, Oda M, Yoshimura K, et al. Vascular endothelial growth factor increases fenestral permeability in hepatic sinusoidal endothelial cells. Liver Int. 2003;23:467-475
11. Geisen P, McColm JR, King BM, Hartnett ME. Characterization of barrier properties and inducible VEGF expression of several types of retinal pigment epithelium in medium-term culture. Curr Eye Res. 2006;31:739-748.
12. Ablonczy Z, Crosson CE. VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res. 2007;85:762-771.
13. Ghassemifar R, Lai CM, Rakoczy PE. VEGF differentially regulates transcription and translation of ZO-1alpha+ and ZO-1alpha- and mediates trans-epithelial resistance in cultured endothelial and epithelial cells. Cell Tissue Res. 2006;323:117-125.
14. Miyamoto N, de Kozak Y, Normand N, et al. PlGF-1 and VEGFR-1 pathway regulation of the external epithelial hemato-ocular barrier. Ophthalmic Res. 2008;40:203-207.
15. Ida H, Tobe T, Nambu H, Matsumura M, Uyama M, Campochiaro PA. RPE cells modulate subretinal neovascularization, but do not cause regression in mice with sustained expression of VEGF. Invest Ophthalmol Vis Sci. 2003;44:5430-5437.
16. Rizzolo LJ. Development and role of tight junctions in the retinal pigment epithelium. Int Rev Cytol. 2007;258:195-234.
17. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Annu Rev Physiol. 2006;68:403-429
18. Powell DW. Barrier function of epithelia. Am J Physiol. 1981;241: G275-G288.
19. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev. 2005;85:845-881.
20. le Moellic C, Boulkroun S, Gonzalez-Nunez D, et al. Aldosterone and tight junctions: modulation of claudin-4 phosphorylation in renal collecting duct cells. Am J Physiol Cell Physiol. 2005;289: C1513-C1521.
21. Chen SY, Bhargava A, Mastroberardino L, et al. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci USA. 1999;96:2514-2519
22. Konrad M, Schaller A, Seelow D, et al. Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet. 2006;79:949-957.
23. Abe T, Sugano E, Saigo Y, Tamai M. Interleukin-1beta and barrier function of retinal pigment epithelial cells (ARPE-19): aberrant expression of junctional complex molecules. Invest Ophthalmol Vis Sci. 2003;44:4097-4104.
24. Luo Y, Zhuo Y, Fukuhara M, Rizzolo LJ. Effects of culture conditions on heterogeneity and the apical junctional complex of the ARPE-19 cell line. Invest Ophthalmol Vis Sci. 2006;47:3644-3655.
25. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
26. Moschos MM, Brouzas D, Apostolopoulos M, et al. Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study-multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol. 2007; 114:37-44.
27. Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. PLoS ONE. 2008;3:e3554.
28. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevaci-zumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48:2814-2823.
29. Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol. 2007;143:995-1002.
30. Peng S, Rahner C, Rizzolo LJ. Apical and basal regulation of the permeability of the retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2003;44:808-817.
31. Gonzalez-Mariscal L, Chavez de Ramirez B, Cereijido M. Effect of temperature on the occluding junctions of monolayers of epithe-lioid cells (MDCK). J Membr Biol. 1984;79:175-184.
32. Claude P. Morphological factors influencing transepithelial permeability: a model for the resistance of the zonula occludens. J Membr Biol. 1978;39:219-232.
33. Reuss L. Tight junction permeability to ions and water. In: Cereijido M, Anderson JM, eds. Tight Junctions. 2nd ed. Boca Raton, FL: CRC Press; 2001:61-88.
34. Tartakoff AM. Laboratory Methods in Vesicular and Vectorial Transport. San Diego, CA: Academic Press; 1991.
35. Eisenman G, Horn R. Ionic selectivity revisited: the role of kinetic and equilibrium processes in ion permeation through channels. J Membr Biol. 1983;76:197-225.
36. Van Itallie CM, Holmes J, Bridges A, et al. The density of small tight junction pores varies among cell types and is increased by expression of claudin-2. J Cell Sci. 2008;121:298-305.
37. Conn G, Bayne ML, Soderman DD, et al. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA. 1990;87:2628-2632.
38. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246: 1309-1312.
39. Gamm DM, Melvan JN, Shearer RL, et al. A novel serum-free method for culturing human prenatal retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2008;49:788-799.
40. Hu J, Bok D. A cell culture medium that supports the differentiation of human retinal pigment epithelium into functionally polarized monolayers. Mol Vis. 2001;7:14-19.
41. Maminishkis A, Chen S, Jalickee S, et al. Confluent monolayers of cultured human fetal retinal pigment epithelium exhibit morphology and physiology of native tissue. Invest Ophthalmol Vis Sci. 2006;47:3612-3624.
42. Rizzolo LJ, Chen X, Weitzman M, Sun R, Zhang H. Analysis of the RPE transcriptome reveals dynamic changes during the development of the outer blood-retinal barrier. Mol Vis. 2007;13:1259-1273.
43. Sun R, Peng S, Chen X, Zhang H, Rizzolo LJ. Diffusible retinal secretions regulate the expression of tight junctions and other diverse functions of the retinal pigment epithelium. Mol Vis. 2008; 14:2237-2262.
44. Gunzel D, Stuiver M, Kausalya PJ, et al. Claudin-10 exists in six alternatively spliced isoforms that exhibit distinct localization and function. J Cell Sci. 2009;122:1507-1517.
45. Kannan R, Zhang N, Sreekumar PG, et al. Stimulation of apical and basolateral VEGF-A and VEGF-C secretion by oxidative stress in polarized retinal pigment epithelial cells. Mol Vis. 2006;12:1649-1659.
46. Shi G, Maminishkis A, Banzon T, et al. Control of chemokine gradients by the retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2008;49(10):4620-4630.
47. Bomsel M, Prydz K, Parton RG, Gruenberg J, Simons K. Endocy-tosis in filter-grown Madin-Darby canine kidney cells. J Cell Biol. 1989;109:3243-3258.
48. Prydz K, Hansen SH, Sandvig K, van Deurs B. Effects of brefeldin A on endocytosis, transcytosis and transport to the Golgi complex in polarized MDCK cells. J Cell Biol. 1992;119:259-272.
49. Wang D, Lehman RE, Donner DB, Matli MR, Warren RS, Welton ML. Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells. Am J Physiol Gastroin-test Liver Physiol. 2002;282:G1088-G1096.
50. Moromizato Y, Hayashi H, Kato H, Ozaki H, Oshima K. Concentration of vascular endothelial growth factor within the subretinal space and vitreous fluid in rhegmatogenous retinal detachment (in Japanese). Nippon Ganka Gakkai Zasshi. 1997;101:498-502.
51. Su CY, Chen MT, Wu WS, Wu WC. Concentration of vascular endothelial growth factor in the subretinal fluid of retinal detachment. J Ocul Pharmacol Ther. 2000;16:463-469.
52. Hou J, Renigunta A, Konrad M, et al. Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. J Clin Invest. 2008;118:619-628.
53. Hou J, Gomes AS, Paul DL, Goodenough DA. Study of claudin function by RNA interference. J Biol Chem. 2006;281:36117-36123.
54. Nakano Y, Kim SH, Kim HM, et al. A claudin-9-based ion permeability barrier is essential for hearing. PLoS Genet. 2009;5: e1000610.
55. Van Itallie CM, Rogan S, Yu A, Vidal LS, Holmes J, Anderson JM. Two splice variants of claudin-10 in the kidney create paracellular pores with different ion selectivities. Am J Physiol Renal Physiol. 2006;291:F1288-F1299.
56. Balda MS, Whitney JA, Flores C, Gonzalez S, Cereijido M, Matter K. Functional dissociation of paracellular permeability and transepi-thelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J Cell Biol. 1996;134:1031-1049.